Who’s Going to AMP 2026

Nov 10–14, 2026 Seattle, WA ~2k attendees Website

305 organizations at the Association for Molecular Pathology (AMP) 2026 Annual Meeting, a ~2,000-person, mostly clinical-lab meeting of molecular pathologists, lab directors and molecular diagnostics teams. As of Oct 6, 2026.

Showing 1–5 of 305 organizations

Organization	AMP 2026 Attendance
MD Anderson Cancer Center Houston, TX
mdanderson.org Med centres Comprehensive cancer center and academic medical institution in Houston, with clinical molecular diagnostics laboratories.	Workshop Wed, Nov 11 10:00am–10:50am Beyond Tissue: Implementing Alternative Analytes for Molecular Diagnostics in Clinical Practice Using cerebrospinal fluid and fine needle aspirate supernatant for sequencing when tumour tissue is scarce or unavailable. Workshop hosted by Thermo Fisher Scientific Skagit 2, Lower Level, Arch at 800 Pike Workshop Wed, Nov 11 12:00pm–12:50pm A New Detection Paradigm for Heme Oncology: High-Color Single-Molecule PCR for Reproducible MRD and Monitoring Single-molecule PCR across millions of partitions to count BCR::ABL1, KMT2A and other blood cancer variants reproducibly. Workshop hosted by Countable Labs Tahoma 2, Level 3, Arch at 800 Pike Workshop Wed, Nov 11 2:00pm–2:50pm Unlocking AML Biology with 5-Base Whole-Genome Sequencing: Integrated Genomic and Epigenomic Profiling for Biomarker Discovery Five-base whole-genome sequencing reads methylation and genomic variation from one AML sample to find research biomarkers. Workshop hosted by Illumina Skagit 1, Lower Level, Arch at 800 Pike Workshop Thu, Nov 12 12:00pm–12:30pm AMP Practice Guidelines Meet the Authors Series: Lung Guideline Update New lung cancer molecular testing recommendations from the updated joint practice guideline, with the evidence and process behind them. Innovation Spotlight Stage #2 Session Fri, Nov 13 10:15am–11:45am Accelerating the Impact of Molecular Profiling in Pediatric and Adolescent Young Adult (AYA) Tumors Ballroom E, Level 6, Arch at 705 Pike Hematopathology · Solid Tumors 10:15am–11:00amFrom Profiling to Clinical Impact: Advancing Molecular Diagnostics for Pediatric and AYA CancersBoston Children's Hospital/ Dana Farber Cancer Institute 11:00am–11:45amMolecular Diagnosis and Surveillance of Bone Marrow Failure and Pediatric MDS:St Jude Children's Research Hospital Session Fri, Nov 13 1:15pm–2:45pm Menin Inhibitors and Targeted Therapy Resistance in AML 608-609, Level 6, Arch at 705 Pike Hematopathology 1:15pm–2:00pmMenin Inhibitor Use in Acute Myeloid LeukemiaJohns Hopkins 2:00pm–2:45pmDevelopment and Use of Menin Inhibitors as Precision Medicines for Acute Myeloid LeukemiaUniversity of Michigan Session Fri, Nov 13 7:00am–8:00am Case Studies in Hematopathology I Hematopathology 7:00am–7:15amWhen FGFR1 Strikes Again: A Rare RBPMS::FGFR1-Driven Myeloid Neoplasm and successful treatment of relapsed disease with PemigatinibMemorial Sloan Kettering Cancer Center 7:15am–7:30amLong read sequencing detection of cytogenetically cryptic insertion of RARA into the PML locus confirming acute promyelocytic leukemia 7:30am–7:45amNovel t(5;12) Fusion Involving ETV6/IL3 Detected by Optical Genome Mapping in Patient with Myelodysplastic Neoplasm with Eosinophilia 7:45am–8:00amRare RUNX1::MIR99AHG Rearranged Acute Myeloid Leukemia with Dual FLT3-ITDs Characterized by Nanopore Long Read SequencingIcahn School of Medicine at Mount Sinai Session Fri, Nov 13 7:00am–8:00am Platform Presentations of Selected HemePath Abstracts I 611-614, Level 6, Arch at 705 Pike 7:00am–7:15amH071 An Epigenomic Foundation Model for Hierarchical WHO/ICC Classification of Hematolymphoid TumorsALMA Genomics 7:15am–7:30amH069 Using Optical Genome Mapping in Standard-of-care of Acute Leukemias: 7 Months’ Clinical ExperienceUniversity of Michigan, Ann Arbor 7:30am–7:45amH068 Real-world Institutional Experience with MassARRAY-based UBA1 Testing for VEXAS SyndromeStanford 7:45am–8:00amH041 Validation and Clinical Application of Comprehensive DNA and RNA NGS for Measurable Residual Disease Assessment of Myeloid NeoplasmsMayo Clinic Workshop Fri, Nov 13 9:30am–10:00am Electronic Genome Mapping for Structural Variant Detection: Implications for Advancing Clinical Research in Heme Malignancies Electronic genome mapping weighed against karyotyping, FISH and optical mapping for structural variants, including marrow versus blood samples. Workshop hosted by Nabsys Innovation Spotlight Stage #1 Talk Sat, Nov 14 10:15am–11:00am Part of Foundation Models in Molecular From AI Promise to Clinical Practice: Which Genomic Foundation Models Can You Trust in Molecular Testing? How well DNA foundation models actually perform on clinical genomic tasks, and how to judge which ones to trust. 608-609, Level 6, Arch at 705 Pike Informatics Talk Sat, Nov 14 10:15am–11:00am Part of Update on the Role of CtDNA-Based Detection of MRD in Clinical Trials and Beyond for Solid Tumors Minimal Residual Disease in Colorectal Cancer: Opportunities for therapeutic development Ballroom E, Level 6, Arch at 705 Pike Solid Tumors Poster Sat, Nov 14 1:45pm–2:00pm Part of Platform Presentations of Selected HemePath Abstracts II H078 Clinical Significance of Clonal Hematopoiesis Detected by Paired Plasma and Peripheral Blood Liquid Biopsy Testing in Patients with Solid Tumors 606-607, Level 6, Arch at 705 Pike Session Sat, Nov 14 2:30pm–4:00pm Technical Advances in Molecular Measurable Residual Disease Detection in Hematologic Neoplasms 611-614, Level 6, Arch at 705 Pike Hematopathology · Technical Topics 2:30pm–2:45pmMeasurable Residual Disease Testing in Acute Myeloid Leukemia: Moving From Theory to PracticeVirginia Tech 2:45pm–4:00pmToward a Paradigm Shift in Personalized Therapies for Lymphoma Using Liquid BiopsiesStanford University Talk Sat, Nov 14 3:00pm–3:30pm Part of Technical Advancement in Methylation Profiling Direct DNA Methylation Analysis by Single Molecule Real-Time Sequencing A transformer model reads polymerase kinetics from SMRT sequencing to call 5mC, 5hmC and 6mA base modifications directly. 608-609, Level 6, Arch at 705 Pike Technical Topics Session Sat, Nov 14 4:15pm–5:15pm Hematopathology Plenary Session 611-614, Level 6, Arch at 705 Pike 4:15pm–5:15pmFrom Genome to Treatment: Tailoring Induction Chemotherapy for Acute Myeloid LeukemiaUniversity of Florida
Mayo Clinic Rochester, MN
mayoclinic.org Med centres Academic medical center and health system whose laboratories develop and run clinical molecular and genomic testing.	Workshop Wed, Nov 11 12:00pm–12:50pm Genome as a Platform: Advancing MRD Research with Illumina Whole Genome Sequencing Oncology Prep Whole-genome sequencing as a single platform for molecular residual disease research, with early analytical performance data. Workshop hosted by Illumina Skagit 5, Lower Level, Arch at 800 Pike Talk Thu, Nov 12 10:45am–11:15am Part of Clinical Applications of Transcriptomics in Lymphomas and Leukemias New Insights from Gene Expression Profiling of Anaplastic Large Cell Lymphoma Gene expression profiling of anaplastic large cell lymphoma and the two newly defined types, I and II, with distinct targetable biology. 608-609, Level 6, Arch at 705 Pike Hematopathology Plenary Thu, Nov 12 1:15pm–2:15pm Part of Solid Tumors Plenary Session DNA Methylation and Artificial Intelligence for the Diagnosis and Classification of CNS Tumors Ballroom ABC, Level 6, Arch at 705 Pike Solid Tumors Workshop Thu, Nov 12 6:15pm–6:45pm Unlocking New Possibilities in Myeloid Malignancies MRD Assessment with NGS An NGS assay for measurable residual disease in myeloid cancers, covering its gene content, workflow and reported performance. Workshop hosted by Thermo Fisher Scientific Innovation Spotlight Stage #1 Talk Fri, Nov 13 10:15am–10:35am Part of Technologist Innovation Session TT009 Assessment of X-Chromosome Inactivation Using Oxford Nanopore Technologies (ONT) Long-Read Sequencing 602-604, Level 6, Arch at 705 Pike Technologist Innovation Session Talk Fri, Nov 13 10:35am–10:55am Part of Technologist Innovation Session ID024 Evaluation of a Targeted Metagenomics Kit for Microbial Identification Using the V1-V2 Region of the 16S Ribosomal RNA Gene 602-604, Level 6, Arch at 705 Pike Technologist Innovation Session Session Fri, Nov 13 1:15pm–2:45pm Clinical Application of Long-read Sequencing Ballroom E, Level 6, Arch at 705 Pike Genetics 1:15pm–1:45pmFully Integrated SNV, Fusion, and Isoform Analysis of Cancer Drivers with Long-read RNA-seq for Improved Functional InterpretationUniversity of California, Santa Cruz 1:45pm–2:15pmImproving Long-Read Sequencing for Transcriptome and Amplicon Sequencing ApplicationsUniversity of California, Santa Cruz 2:15pm–2:45pmClinical Implementation of Long-Read Sequencing: From Targeted Assays to Genome SequencingStanford University School of Medicine Talk Fri, Nov 13 7:15am–7:30am Part of Case Studies in Genetics I Long-Read Sequencing Improves Diagnostic Efficiency and Workflow for NCF1 Testing in Chronic Granulomatous Disease Genetics Poster Fri, Nov 13 7:45am–8:00am Part of Platform Presentations of Selected HemePath Abstracts I H041 Validation and Clinical Application of Comprehensive DNA and RNA NGS for Measurable Residual Disease Assessment of Myeloid Neoplasms 611-614, Level 6, Arch at 705 Pike Talk Sat, Nov 14 10:15am–10:45am Part of Current and Emerging Methods for Structural Variants and Gene Fusions FISH vs. RNA sequencing for Structural Variant Detection in Solid Tumors: Strengths and Limitations Case-based comparison of break-apart FISH and RNA sequencing for finding gene rearrangements in solid tumors, including FFPE pitfalls. 611-614, Level 6, Arch at 705 Pike Hematopathology · Lab Management · Solid Tumors Session Sat, Nov 14 10:15am–11:45am Foundation Models in Molecular 608-609, Level 6, Arch at 705 Pike Informatics 10:15am–11:00amFrom AI Promise to Clinical Practice: Which Genomic Foundation Models Can You Trust in Molecular Testing?The University of Texas MD Anderson Cancer Center 11:00am–11:45amA Bioinformatician's Guide to Choosing Biological Foundation Models in 2026Genomics England; Rewire-bio (independent side project) Poster Sat, Nov 14 2:00pm–2:15pm Part of Platform Presentations of Selected Genetics Abstracts II G075 UGT1A1 Genotyping for Pharmacogenomics Testing: Is Sequencing Necessary? 608-609, Level 6, Arch at 705 Pike Talk Sat, Nov 14 2:30pm–3:00pm Part of Interactive Visualization Tools for Molecular Testing CNVpytor: Comprehensive Detection, Annotation, and Visualization of Germline and Somatic Copy Number Variations CNVpytor, a tool combining read depth and B-allele frequency to call and visualize germline and somatic copy number changes. 606-607, Level 6, Arch at 705 Pike Informatics Poster Sat, Nov 14 7:30am–7:45am Part of Platform Presentations of Selected Solid Tumors Abstracts I ST094 MET Exon 14 Skipping Discordance as a Tool for Quality Improvement in Clinical NGS Testing Ballroom E, Level 6, Arch at 705 Pike
Palmetto GBA Columbia, SC
palmettogba.com Gov/NGO Medicare Administrative Contractor that runs the MolDX program, setting coverage and reimbursement policy for molecular diagnostic tests.	Session Thu, Nov 12 10:15am–11:45am Technical Advancement in Spatial Genomics and Multi-omics 602-604, Level 6, Arch at 705 Pike Solid Tumors · Technical Topics 10:15am–11:00amSpatial Multi-Omics Profiling in TissuesUniversity of Pennsylvania 11:00am–11:45amMolecular-Resolution Spatial Inference of Subcellular Transcriptional ProgramsUniversity of Michigan Session Fri, Nov 13 10:15am–11:45am Technologist Innovation Session 602-604, Level 6, Arch at 705 Pike Technical Topics 10:15am–10:35amTT009 Assessment of X-Chromosome Inactivation Using Oxford Nanopore Technologies (ONT) Long-Read SequencingMayo Clinic 10:35am–10:55amID024 Evaluation of a Targeted Metagenomics Kit for Microbial Identification Using the V1-V2 Region of the 16S Ribosomal RNA GeneMayo Clinic 10:55am–11:15amG010 Comparison of Manual Illumina PCR-Free and Hamilton NGS STAR Automated Library Preparation for Germline Whole Genome SequencingToronto General Hospital 11:15am–11:35amH010 Laboratory Developed Test Validation of FL24Cx: A Gene Expression Profiling Assay to Predict Risk of Early Events in Follicular LymphomaUniversity of Arizona Session Fri, Nov 13 3:45pm–4:45pm Technical Topics Plenary Session Ballroom ABC, Level 6, Arch at 705 Pike Technical Topics 3:45pm–4:45pmStepping Towards Single-Molecule Protein Sequencing Using NanoporesUniversity of Washington Session Sat, Nov 14 2:30pm–4:00pm Technical Advances in Molecular Measurable Residual Disease Detection in Hematologic Neoplasms 611-614, Level 6, Arch at 705 Pike Hematopathology · Technical Topics 2:30pm–2:45pmMeasurable Residual Disease Testing in Acute Myeloid Leukemia: Moving From Theory to PracticeVirginia Tech 2:45pm–4:00pmToward a Paradigm Shift in Personalized Therapies for Lymphoma Using Liquid BiopsiesStanford University
Endeavor Health & University of Chicago Pritzker School of Medicine Evanston, IL
endeavorhealth.org Med centres Multi-hospital system in suburban Chicago and its affiliated medical school, running clinical molecular microbiology and virology laboratories.	Session Fri, Nov 13 1:15pm–2:45pm Quality Monitoring in the Molecular Microbiology Laboratory: Practical Compliance from Smaller vs. Larger Labs 606-607, Level 6, Arch at 705 Pike Infectious Diseases · Lab Management 1:15pm–2:00pmQuality Monitoring in Molecular MicrobiologyUniversity of Vermont, UVM Health, UVM Medical Center 1:15pm–2:45pmSignal or Noise? Quality Monitoring in a Molecular Microbiology Reference LaboratoryUniversity of Washington School of Medicine Session Sat, Nov 14 10:15am–11:45am Molecular Viral Diagnostics for the Immunocompromised Host: Practical Applications and Ongoing Struggles 602-604, Level 6, Arch at 705 Pike Infectious Diseases 10:15am–11:00amProgress and Challenges in Standardization of Quantitative Transplant Virus TestingSt. Jude Children's Research Hospital 11:00am–11:45amThe If, When, and How of Antiviral Resistance Testing for the Immunocompromised HostCleveland Clinic Session Sat, Nov 14 8:15am–9:15am Infectious Diseases Plenary Session Ballroom ABC, Level 6, Arch at 705 Pike Infectious Diseases 8:15am–9:15amArtificial Intelligence for Antimicrobial Resistance (and Susceptibility!) PredictionsVanderbilt University Medical Center
Memorial Sloan Kettering Cancer Center New York, NY
mskcc.org Med centres Cancer hospital and research institute in New York with a large clinical tumour sequencing and molecular diagnostics programme.	Session Thu, Nov 12 1:15pm–2:15pm Solid Tumors Plenary Session Ballroom ABC, Level 6, Arch at 705 Pike Solid Tumors 1:15pm–2:15pmDNA Methylation and Artificial Intelligence for the Diagnosis and Classification of CNS TumorsMayo Clinic Talk Thu, Nov 12 2:30pm–3:00pm Part of AMP Clinical Practice Committee Work in Progress Updates - NGS Validation and Reporting AMP Clinical Validation of cfDNA and ctDNA Assays Working Group Setting validation standards for liquid biopsy assays in oncology, with attendee input shaping the guideline under development. Ballroom E, Level 6, Arch at 705 Pike Talk Thu, Nov 12 3:00pm–3:30pm Part of AMP Clinical Practice Committee Work in Progress Updates - NGS Validation and Reporting AMP Copy Number Alterations Working Group Copy number alterations called from sequencing: how those assays are validated, reported and read next to FISH, cytogenetics and microarray. Ballroom E, Level 6, Arch at 705 Pike Workshop Thu, Nov 12 4:25pm–4:55pm Want to get involved with AMP? Volunteering pathways in the professional society, from short time-limited tasks through committee membership and leadership roles. Innovation Spotlight Stage #3 Session Fri, Nov 13 10:15am–11:45am Accelerating the Impact of Molecular Profiling in Pediatric and Adolescent Young Adult (AYA) Tumors Ballroom E, Level 6, Arch at 705 Pike Hematopathology · Solid Tumors 10:15am–11:00amFrom Profiling to Clinical Impact: Advancing Molecular Diagnostics for Pediatric and AYA CancersBoston Children's Hospital/ Dana Farber Cancer Institute 11:00am–11:45amMolecular Diagnosis and Surveillance of Bone Marrow Failure and Pediatric MDS:St Jude Children's Research Hospital Talk Fri, Nov 13 11:15am–11:45am Part of Resolving the Unknown: Functional and Computational Approaches to Determine Pathogenicity of Genetic Variants AlphaMissense for Identifying Pathogenic Missense Mutations in DNA Damage Repair Genes in Cancer Using AlphaMissense and related AI tools to flag pathogenic missense variants in DNA damage repair genes in cancer. 611-614, Level 6, Arch at 705 Pike Genetics Talk Fri, Nov 13 1:15pm–2:45pm Part of Optimizing Computational Infrastructure for High-throughput Clinical Data Data Analysis, Interpretation, and Discovery in 100,000 Patients With Cancer Combining somatic, germline and clinical data from over 100,000 cancer patients to support variant interpretation, trials and discovery. 611-614, Level 6, Arch at 705 Pike Informatics Talk Fri, Nov 13 7:00am–7:15am Part of Case Studies in Hematopathology I When FGFR1 Strikes Again: A Rare RBPMS::FGFR1-Driven Myeloid Neoplasm and successful treatment of relapsed disease with Pemigatinib Hematopathology Session Sat, Nov 14 10:15am–11:45am Update on the Role of CtDNA-Based Detection of MRD in Clinical Trials and Beyond for Solid Tumors Ballroom E, Level 6, Arch at 705 Pike Solid Tumors 10:15am–11:00amMinimal Residual Disease in Colorectal Cancer: Opportunities for therapeutic developmentThe University of Texas MD Anderson Cancer Center, Houston, TX 11:00am–11:45amLiquid Biopsy Biomarkers for Early Detection of Treatment Response and Disease MonitoringMCGill University, Research Institute of the McGill University Health Centre Session Sat, Nov 14 1:15pm–2:15pm Platform Presentations of Selected Solid Tumor Abstracts II 611-614, Level 6, Arch at 705 Pike 1:15pm–1:30pmST026 Comparative Analysis of Copy Number Variant Detection from DNA Methylation Arrays Against Targeted Next-Generation Sequencing in a Pan-Cancer CohortNYU Langone Health 1:30pm–1:45pmST074 Integration of Longitudinal ctDNA Sequencing and Quantitative ESR1 Mutation Analysis to Inform Molecular Monitoring Strategies in Metastatic Breast CancerEarle A Chiles Research Institute, Providence Health 1:45pm–2:00pmST015 Clinical Evaluation of Whole Genome Enzymatic Methylation Sequencing for Integrated Classification and Copy Number Profiling of Pediatric Central Nervous System TumorsChildren's Hospital Los Angeles, University of Southern California 2:00pm–2:15pmST093 Tumor Cellularity Limits Next-Generation Sequencing Sensitivity for MTAP Loss: Post-Validation Next-Generation Sequencing-Immunohistochemistry Concordance in a Large Single-Institution CohortM.D. Anderson Cancer Center

Instantly find 20 buyers from companies at AMP 2026

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

When and where is AMP 2026?

AMP 2026 Annual Meeting & Expo runs November 10–14, 2026, at the Seattle Convention Center in Seattle, WA.

What are the AMP 2026 exhibit hall hours?

The exhibit hall is open Thu, Nov 12, 11:15am–7:00pm; Fri, Nov 13, 9:00am–4:00pm; Sat, Nov 14, 9:00am–1:30pm.

Where is the AMP 2026 program?

This guide lists every organization on the AMP 2026 program with its sessions; the full program is on the official website.

How do I register for AMP 2026?

Fees and registration are on the organizer's registration page.

Where does this list come from?

AMP’s own public exhibitor floor plan, program, presenter list and sponsor page. Nothing here requires a login.

How current is it?

Pulled 6 October 2026. Exhibitor and program lists keep growing until the meeting.

Why are there no names?

This guide is about which organizations are in the room, not which people. It publishes a speaking role and a count, never a presenter’s name.

Browse AMP 2026 by

Organization type

Program track

Exhibit hall

Exhibitors 184

Everyone

All organizations A–Z 305

Organizations with their own page

192 organizations — every exhibitor and every organization with 1 or more presentations.

Not affiliated with the Association for Molecular Pathology. Organization details are derived from AMP’s published lists. Submit a correction